Exon 20 Group, a multistakeholder organization

This account is verified. Learn more

@Exon20Group

Global org: patients/carers, HCPs, pharma, labs, scientists, working to cure #NSCLC #HER2 & #EGFR #Exon20 insertions (in 25 cancers +) marcia@exon20group.org

93 countries served exon20group.org Joined July 2017

3.4K Following 2.2K Followers 2.1K Posts

Latest posts 5

Pinned post

Exon 20 Group, a multistakeholder organization @Exon20Group Apr 26, 2023

Replying to @JennyCarlisleMD

Don’t let your #EGFR #Exon20 and #HER2 #Exon20 patients miss out on the wonderful, caring community of patients and care partners (+ family members) in the multi-stakeholder @Exon20Group We have peer-to-peer counseling through our Angel Buddies program, oncology nursing services, weekly virtual meetings, and direct patient navigation plus 20 closed Facebook groups and Inspire. Ami and mobo as well as the drugs in the clinical trials pipeline are vitally important & manageable. We are looking for additional investigators, so let us know! Clinicians, molecular profiling labs welcome. Join our Exon 20 International Research Consortium! All services are free, exon20group.org & marcia@exon20group.org

Exon 20 Group, a multistakeholder organization @Exon20Group 2d

Congrats to Dr. Barbara Burtness at @YaleCancer and OrigAMI-4 patients, families, and study teams. This is a tremendous advance for recurrent/metastatic #HNSCC patients post plat chemo and anti-PD-(L)1. Accelerated approval based on ORR and DOR is merited, and we are thrilled for #HNSCC patients who can now benefit. Yet another solid tumor feather added to ami's cap.

Yale Cancer Center Verified account @YaleCancer 2d

The #FDA granted accelerated approval of amivantamab and hyaluronidase-lpuj for patients with recurrent or metastatic head and neck squamous cell carcinoma #HNSCC. An exciting development for patients and we congratulate Dr. Barbara Burtness on her work and leadership in the field!
➡️bit.ly/4iIrWpv
@SmilowCancer @YNHH

View quoted post on X

Exon 20 Group, a multistakeholder organization @Exon20Group Oct 29

Must/reading, for our #HER2 Exon 20 Warriors in the @Exon20Group …#LCSM

Stephen V Liu, MD Verified account @StephenVLiu Oct 29

Report on zongertinib and CNS disease in pts with advanced HER2 mutant NSCLC @JTOonline. In 4 cases, pts received escalated doses of zongertinib at 240mg with variable effect but one case was able to continue at the higher dose for 30 months.

jtocrr.org/article/S2666-…

View quoted post on X

Exon 20 Group, a multistakeholder organization @Exon20Group Oct 28

Let’s get IT HP for #NSCLC #HER2 #exon 20 patients (especially for those who are also HER2 IHC positive) or let’s get an IIT working on IT Enhertu. If anyone is using IT Enhertu for #HER2 #Ex20 lung or other tumor types driven by #HER2 #Ex20, let us know!

Hope Rugo @hoperugo Oct 26

#ESMO2026 2 interesting presentations on HER2 isolated brain Mets and LMD. Tucatinib HP for brain Mets and IT HP for LMD. Remarkable efficacy for both! Impact on clinical practice. @OncoAlert

View quoted post on X

Exon 20 Group, a multistakeholder organization @Exon20Group Oct 28

Such important work, and we are so grateful for your leadership along with your colleagues, @PTarantinoMD

Paolo Tarantino Verified account @PTarantinoMD Oct 26

Honored to have the opportunity to present the results from our translational #CHARISMA study, unveiling mechanisms of resistance to TOPO1 ADC. A true team work involving the amazing @DFCI_BreastOnc research teams and @AstraZeneca Translational Medicine. 🧬 #ESMO26
View quoted post on X